Metabolic complications associated with the use of highly active antiretroviral therapy in HIV-1-infected adults

American Journal of the Medical Sciences

Volumn 328, Issue 1, 2004, Pages 48-56

  Monier, Paul L ^a   Wilcox, Ronald ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

AIDS; HIV; Insulin resistance; Lipodystrophy; Metabolic complications

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

BODY FAT; BONE DISEASE; BONE NECROSIS; DYSLIPIDEMIA; GLUCOSE INTOLERANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIPOATROPHY; MEDICAL SOCIETY; MORBIDITY; MORTALITY; OSTEOPENIA; OSTEOPOROSIS; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT;

EID: 3242718713     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200407000-00007     Document Type: Article

References (78)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
2. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving protease inhibitors. AIDS 1998;12:F51-8.
3. Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1 infected patients. AIDS 1998;F167-F73.
4. Miller KD, Jones E, Yanovski JA, et al. Visceral abdominal fat accumulation associated with the use of indinavir. Lancet 1998;351:871-5.
5. Lo JC, Mulligan K, Tai VW. "Buffalo hump" in men with HIV-1 infection. Lancet 1998;351:867-70.
6. Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. November 2003.
7. Schambelan M, Benson CB, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002;31:257-75.
8. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus-infected adults receiving antiretroviral therapy: recommendations of the HIV medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003;37:613-27.
9. Grunfeld C, Pang M, Doerrler W, et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992;74:1045-52.
10. Grunfield C, Kotler DP, Hamadeh R, et al. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989;86:27-31.
11. Feingold IM, Krauss RM, Pang M, et al. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Metab 1993;76:1423-7.
12. Shor-Posner G, Basit A, Lu Y, et al. Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J Med 1993;94:515-9.
13. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999;13:F63-70.
14. Mulligan K, Grunfield C, Tai W, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV-1 infection. J Acquir Immune Defic Syndr 2000;23:35-43.
15. Berthold HK, Parhofer KG, Ritter MM, et al. Influence of protease inhibitor therapy on lipoprotein metabolism. J Intern Med 1999;246:567-75.
16. Kumar P, Rodriguez-French A, Thompson M, et al. Prospective study of hyperlipidemia in ART-naïve subjects taking combivir/abacavir, cobivir/nelfmavir, or stavudine/lamivudine [abstract 33]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002.
17. Eron JJ, Murphy RL, Peterson D, et al. A comparison of stavudine, didanosine, and indinavir with zidovudine, lamivudine, and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II). AIDS 2000;14:1601-10.
18. Van Leth F, Phanuphak P, Gazzard B, et al. Lipoid changes in a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine (2NN Study) [abstract 752]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003. p. 328.
19. Van Der Valk M, Kastelein JJ, Murphy RL, et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001;15:2407-14.
20. Gatell J, Squires K, Pilierop P, et al. Atazanavir: Absence of serum lipid changes after 48 weeks of treatment in treatment-naïve HIV-positive subjects (Trial AI424-007). Antivir Ther 2001;6(S4):49.
21. Haas D, Zala C, Schrader S, et al. Once-daily atazanavir plus saquinavir favorably affects total cholesterol and fasting triglyceride profiles in patients failing prior PI therapy (Trial AI424-009) [abstract LB-16]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 2001.
22. Roberts AD, Muesing RA, Parenti DM, et al. Alterations in serum levels of lipids and lipoproteins with indinavir therapy for human immunodeficiency virus-infected patients. Clin Infect Dis 1999;29:441-3.
23. Sullivan AK, Feher MD, Nelson MR, et al. Marked hypertriglyceridemia associated with ritonavir therapy. AIDS 1998;12:1393-4.
24. Carr A, Samaras K, Chisholm DJ, et al. Pathogenesis of HIV-1-protease inhibitor-associated lipodystrophy, hyperlipidemia, and insulin resistance. Lancet 1998;351:1881-3.
25. Smart EJ, Matveev S, Kencer J, et al. Protease inhibitors up-regulate SR-BI and HDL-dependent cholesterol uptake in human macrophages: a mechanism that may enhance foam cell formation [abstract 662]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 2001.
26. Lenhard JM, Furfine ES, Jain RG, et al. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. Antiviral Res 2000;47:121-9.
27. Lenhard JM, Croom DK, Weiel JE, et al. HIV protease inhibitors stimulate hepatic triglyceride synthesis. Arterioscler Thromb Vasc Biol 2000;20:2625-9.
28. Perry RC, Cushing HE, Deeg MA, et al. Ritonavir, triglycerides, and pancreatitis. Clin Infect Dis 2000;30(S2):S135-42.
29. Friis-Moller N, Weber R, Monforte D, et al. Exposure to HAART is associated with an increased risk of myocardial infarction: the D:A:D Study [abstract 130]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003.
30. Rickerts V, Brodt H, Staszewski S, et al. Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-Cohort Study. Eur J Med Res 2000;5:329-33.
31. Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002;360:1747-8.
32. Mary-Krause M, Cotte L, Partisani M, et al. Impact of treatment with protease inhibitors on myocardial infarction occurrence in HIV-infected men [abstract 657]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 2001. p. 241.
33. Bozette SA, Ake CF, Tam HK, et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003;348:702-10.
34. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the 3rd report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
35. Clumeck N, Goebel F, Rozenbaum W, et al. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1 infected patients with undetectable plasma HIV-1 RNA. AIDS 2001;15:1517-26.
36. Martinez E, Cognet I, Lozano L, et al. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999;13:805-10.
37. Barreiro P, Soriano V, Blanco F, et al. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 2000;14:807-12.
38. Negredo E, Cruz L, Paredes R, et al. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin Infect Dis 2002;34:504-10.
39. Murphy R, Pokrovsky V, Giordano M, et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir: 108-week results of BMS study 008/044 [abstract 555]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003.
40. Mastroianni CM, d'Ettorre G, Forcina, et al. Rhabdomyolysis after cerivastatin-gemfibrozil therapy in an HIV-1 infected patient with protease inhibitor-related hyperlipidemia. AIDS 2001;15:820-1.
41. Roth VR, Kravcik S, Angel JB. Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis 1998;27:65-7.
42. Galli M, Veglia F, Angarano G, et al. Risk of developing metabolic and morphologic alterations under antiretroviral therapy according to the drug combinations. Antivir Ther 2000;31:1482-7.
43. Heath KV, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001;15:231-9.
44. Thiebaut R, Daucourt V, Mercie P, et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Clin Infect Dis 2000;31:1482-7.
45. Lichtenstein KA, Ward DJ, Moorman AC, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001;15:1389-98.
46. Martinez E, Mocroft A, Garcia-Viejo M, et al. Risk of lipodystrophy in HIV-1 infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001;357:592-8.
47. Mallal SA, John M, Moore CB, et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000;14:1309-16.
48. Carr A, Hudson J, Chuah J, et al. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicenter study. AIDS 2001;15:1811-22.
49. Martinez E, Conget I, Lozano L, et al. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999;13:805-10.
50. Martinez E, Garcia-Viejo MA, Blanco JL, et al. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin Infect Dis 2000;31:1266-73.
51. Domingo P, Francia E, Torres O, et al. Differential effects of zidovudine and stavudine on fat distribution and its associated metabolic abnormalities in HIV-1 infected patients on highly active antiretroviral therapy [abstract ThOrB705]. In: Programs and abstracts of the 13th International AIDS Conference (Durban). 2000. p. 296.
52. Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 2002;288:207-15.
53. McComsey G, Lonergan T, Fisher R, et al. Improvements in lipoatrophy are observed after 24 weeks when stavudine is replaced by either abacavir or zidovudine [abstract 701-T]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002.
54. John M, James I, McKinnon E, et al. A randomized, controlled, open-label study of revision of antiretroviral regimens containing stavudine and/or a protease inhibitor to zidovudine/lamivudine/abacavir to prevent or reverse lipoatrophy [abstract 700-T]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002.
55. Wanke C, Gerrior J, Kantaros J, et al. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 1999;13:2099-103.
56. Mauss S, NVolf E, Jaeger H. Reversal of protease inhibitor-related visceral abdominal fat accumulation with recombinant human growth hormone. Ann Intern Med 1999;131:313-4.
57. Marin P, Oden B, Bjorntorp P. Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. J Clin Endocrinol Metab 1995;80:239-43.
58. Saint-Marc T, Touraine JL. Effects of metformin on insuline resistance and central adiposity in patients receiving effective protease inhibitor therapy. AIDS 1999;13:1000-2.
59. Hadigan C, Corcoran C, Basgoz N, et al. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 2000;284:472-7.
60. Sutinen J, Hakkinen AM, Westerbacka J, et al. Rosiglitazone in the treatment of HAART associated lipodystrophy: a randomized, double-blind, placebo-controlled study [abstract LB13]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002.
61. Calmy A, Hirschel B, Karsegaard L, et al. A pilot study for the use of pioglitazone in the treatment of highly active antiretroviral therapy lipodystrophy syndromes. Antivir Ther 2001;6(S4):32.
62. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001;32:130-9.
63. Mynarcik DC, McNurlan MA, Steigbigel RT. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 2000;25:312-1.
64. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000;275:20251-4.
65. American Diabetes Association. Standards of medical care of patients with diabetes mellitus. Diabetes Care 2003;26(S3):33-50.
66. Gelato M, Mynarcik DC, McNurlan MA. Rosiglitazone mediated restoration of subcutaneous fat and improvement in insulin sensitivity in HIV-associated lipodystrophy. J Invest Med 2002;50:177A.
67. Mondy K, Tebas P. Emerging bone problems in patients infected with human immunodeficiency virus. Clin Infect Dis 2003;36:s101-5.
68. Jacobson D, Knox T, Shevitz A, et al. Low bone mineral density in HIV-infected women [abstract 102]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003.
69. Arnsten JH, Freeman R, Santoro N, et al. HIV infection and protease inhibitor use are not associated with reduced bone mineral density in older HIV-infected women [abstract 103]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003.
70. McGowan I, Cheng A, Coleman S, et al. Assessment of bone mineral density in HIV-infected antiretroviral naïve patients [abstract 628]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 2003.
71. Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000;14:F63-7.
72. Monier P, McKown K, Bronze MS. Avascular necrosis of bone in patients with human immunodeficiency virus infection. Clin Infect Dis 2000;31:1488-92.
73. Miller KD, Masur H, Jones EC, et al. High prevalence of osteonecrosis of the femoral head in HIV-infected adults. Ann Intern Med 2002;137:17-25.
74. Schambelan M, Benson CA, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: Recommendations of an International AIDS Society-USA Panel. J Acquir Immune Defic Syndr 2002;31:257-75.
75. Masur H. Perspectives: Metabolic complications in HIV disease: lactemia and bone disease. Topics HIV Med 2001;9:8-11.
76. Brivet PG, Nion I, Megarbane B, et al. Fatal lactic acidosis and liver steatosis associated with didanosine and stavudine treatment: a respiratory chain dysfunction? [letter] J Hepatol 2000;32:364-5.
77. Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001;357:280-1.
78. Peterson PL. The treatment of mitochondrial myopathies and encephalomyopathies. Biochim Biophys Acta 1995;1271:275-80.